Table 3.
Interferon free combination strategies in development
| Mechanism | Drugs | Trial phase | Patients | Virological response, end point | References |
|---|---|---|---|---|---|
| Nucleoside polymerase +NS3 protease inhibitor | Daclatasvir + asunaprevir | II | Genotype-1, null responders, USA | RVR 64%, SVR 36% (n = 11) | Lok et al. 2012 [58] |
| II | Genotype-1b, null reponders, Japan | SVR24 100% (n = 10) | Chayama et al. 2012 [79] | ||
| Nucleoside polymerase inhibitor + RBV | GS-7977 +RBV | II | Genotype-2 and -3, naïve | RVR 100%, SVR 100% (n = 10) | Gane et al. 2011 [51] |
| II | Genotype-1, null responders | SVR4 10% (n = 10) | Gane et al. 2012 [52] | ||
| Nucleoside polymerase +NS3 protease inhibitor +Ribavirin | BI201335 +BI207127 +RBV | II | Genotype -1, naïve | RVR 100% (n = 17) | Zeuzem et al. 2011 [90] |
| Nucleoside polymerase +NS3 protease inhibitor | Tegobuvir +GS-9256 | II | Genotype-1, naïve | EVR 80% (n = 15) +RBV: EVR 100%) (n = 13) | Foster et al. 2011 [86] |
| Nucleoside polymerase +NS3 protease inhibitor | Mericitabine +danoprevir | II | Genotype-1, experienced, non-responders | Day14 viral load −4.9 log10 IU ml−1 | Gane et al. 2010 [55] |
| II | Genotype-1, naïve | Day14 viral load −5.1 log10 IU ml−1 | Gane et al. 2010 [55] |
PEG-IFN, pegylated interferon alpha-2a/b; RBV, ribavirin; RVR, rapid virological response with HCV RNA undetectable at week 4; EVR, early virological response with HCV RNA undetectable at week 12.